Abcam, ab238968, Anti-DHODH antibody [EPR11814] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal DHODH antibody. Carrier free. Suitable for WB and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR11814,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab238968 is the carrier-free version of
ab174288
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Dihydroorotate dehydrogenase (DHODH) also known as URA1 is an enzyme weighing approximately 43 kDa. It plays a critical role in the de novo pyrimidine biosynthesis pathway. DHODH is mainly expressed in the inner mitochondrial membrane where it catalyzes the conversion of dihydroorotate to orotate. This reaction involves ubiquinone as an electron acceptor making DHODH an important player in cellular respiration. Its functionality is essential for the synthesis of nucleotides particularly in rapidly proliferating cells.
Biological function summary
Dihydroorotate dehydrogenase is involved in establishing the pyrimidine pool necessary for DNA and RNA synthesis. It is a single-component enzyme but its activity supports the function of other enzymes in the pathway such as carbamoyl-phosphate synthetase. The proper regulation of DHODH is integral to cellular proliferation and immune responses. Cells that synthesize nucleotides at high rates such as immune cells and cancer cells heavily depend on its activity.
Pathways
Dihydroorotate dehydrogenase is an important player in the pyrimidine biosynthesis pathway and links to the mitochondrial electron transport chain. Its interaction with ubiquinone underlines its role in energy production connecting it to respiratory complexes. DHODH works alongside proteins such as orotate phosphoribosyltransferase which further transforms orotate to orotidine-5'-monophosphate in pyrimidine biosynthesis. These pathways are vital for maintaining the balance of nucleotide levels impacting processes like DNA replication.
Dihydroorotate dehydrogenase is relevant to autoimmune diseases like rheumatoid arthritis and cancers. Inhibitors such as leflunomide and brequinar target DHODH to disrupt the proliferation of rapidly dividing cells. Leflunomide which is metabolized to teriflunomide reduces immune cell turnover in rheumatoid arthritis illustrating DHODH's therapeutic importance. Similarly it is a target in cancer treatment where its inhibition can slow down tumor growth interfacing with other metabolic regulators active in malignancies.